MOMerve Oruc

Merve Oruc

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Merve Oruc has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Silent Brain Lesions in Chronic Kidney Disease: A Hidden Burden

    by İsmail Baloğlu, Yasin Öztürk, Cemile Feyza Elbistan, Merve Oruç, Mehmet Burak Erçin, Hakan Ozer, Fethi Yönet, Hasan Hüseyin Kozak, Ganime Dilek Emlik, Nedim Yılmaz Selçuk, et al.

    Objective: Silent brain lesions (SBL), including silent brain infarction (SBI) and subcortical white matter lesions (SWML), are increasingly recognized as important radiological markers of cerebral small vessel disease. Patients with chronic kidney disease (CKD) may be at increased risk due to shared vascular and metabolic abnormalities. This study aimed to investigate the prevalence, radiological characteristics, and predictors of SBL in patients with CKD.Methods: This retrospective study included 276 patients with CKD who underwent brain magnetic resonance imaging (MRI) between March 2020 and March 2021. CKD was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m², and patients undergoing hemodialysis were included. MRI findings were classified as SBI, SWML, overt stroke, or no lesion. Silent brain lesions were defined as the presence of SBI and/or SWML in patients without a clinical history of stroke or focal neurological deficits. Clinical and laboratory data were analyzed, and independent predictors were determined using binary logistic regression.Results: Pathological MRI findings were detected in 177 patients (64.1%). Among them, 131 patients (74.0%) had SBL (73 SWML and 58 SBI), while 46 (26.0%) had overt stroke. Patients with SBL were older and had a higher prevalence of diabetes mellitus and hypertension compared with those with overt stroke. In multivariate logistic regression analysis, older age (OR: 1.073, 95% CI: 1.051–1.096; p < 0.001) and higher serum creatinine levels (OR: 1.306, 95% CI: 1.096–1.557; p = 0.003) were identified as independent predictors of SBL. Among patients with SBL, those with SWML had a longer duration of hemodialysis compared to those with SBI.Conclusion: Silent brain lesions are highly prevalent in patients with CKD. Older age and impaired renal function are independent predictors of SBL. These findings highlight the importance of cerebrovascular risk assessment in CKD patients, particularly in older individuals and those with advanced renal dysfunction.

  • Open Access

    The relationship between urinary MMP-9, proteinuria, and pulse wave velocity in patients with diabetic kidney disease: a cross-sectional study

    by Mehmet Burak Erçin, Ismail Baloglu, Ayse Kul, Fethi Yonet, Yasin Ozturk, Merve Oruc, Aleyna Terzi, İbRahim Kılınc, Kultigin Turkmen

  • Open Access

    The effect of symptomatic extra-articular manifestations of rheumatoid arthritis on disease activity and patient-reported outcomes: a cross-sectional and observational study

    by Ahmet Oruç, Hasan Satış, Merve Oruç, Reyhan Bilici, Abdurrahman Tufan, Mehmet Akif Öztürk

    Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints but also has extra-articular manifestations. Extra-articular manifestations (EAMs) in RA encompass a wide range of clinical findings that may significantly affect patients’ quality of life. This study aimed to compare daily life, social function, and work productivity between RA patients with and without EAMs. In this study, we aimed to determine the differences in daily life, social life, and work between patients with and without EAM. Methods: This cross-sectional and observational study included 402 RA patients (2010 ACR-EULAR). EAM was defined as systemic symptoms and organ involvement occurring outside of the joint findings caused by RA. The presence of EAM was grouped as symptomatic/asymptomatic. Patients were evaluated once during the study period in an outpatient setting. Patients completed the Health Assessment Questionnaire (HAQ), Short Form-36 (SF-36), and Work Productivity and Activity Impairment: General Health (WPAI: GH) forms under clinician observation. Continuous variables were compared using the Mann–Whitney U test and Independent Samples T-test, while Fisher’s exact test or chi-square test was used for categorical variables. The significance level was set at 5% ( p < 0.05). Results: The study included 402 patients. 325 (80.8%) were female, with a median (IQR) age of 56 (47–64.25) and a mean±standard deviation (SD) disease duration of 9.7 ± 8.6 years. EAM was present in 200 patients. Patients were classified as having symptomatic EAM (sEAM) (n = 81), asymptomatic EAM (asEAM) (n = 119), and no EAM (n = 202). The median age was 60 (54.5–67), and the median age at diagnosis was 49 (39.5–58) in the sEAM group, which had the highest values (p:<0.001 and p:0.003, respectively). Peripheral neuropathy detected in 24 (29.6%) patients was the most common symptomatic EAM, while keratoconjunctivitis sicca detected in 44 (36.9%) patients was the most common asymptomatic EAM. In sEAM patients, HAQ mean ± SD was 0.92 ± 0.73, while in non-EAM patients it was 0.68 ± 0.65, p = 0.021. In SF-36 results, physical function, social function, role physical, vitality, and mental health were statistically significantly lower in patients with sEAM compared to other groups. The percentage of working patients was higher at 28.2% in those without EAM, p:0.010. Absenteeism, mean ± SD, was higher in the sEAM group at 12.8 ± 28.1, p: 0.037, and activity impairment was also higher in sEAMs at mean ± SD 44.2 ± 29.1, p:0.025. Conclusions: Regardless of RA disease activity, patients with sEAM experience negative impacts on both their daily and social lives as well as their work life. Symptomatic EAMs are associated with significant impairment in quality of life and work productivity, independent of traditional disease activity measures. Clinicians should therefore systematically assess and manage these manifestations as an integral component of RA care.

  • Open Access

    The effect of tolvaptan on total kidney volume and inflammatory markers in autosomal dominant polycystic kidney disease

    by Merve Oruc, Mehmet Burak Ercin, Ahmet Oruc, Kultigin Turkmen, Ismail Baloglu

    Background: Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst growth, kidney enlargement, and decline in renal function. Increasing evidence suggests that inflammatory processes may contribute to disease progression. This study aimed to evaluate the association between tolvaptan use, systemic inflammatory markers, and total kidney volume (TKV) progression in patients with ADPKD. Methods: This retrospective study included 67 patients with ADPKD, including 40 receiving tolvaptan and 27 untreated controls. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), estimated glomerular filtration rate (eGFR), and TKV were evaluated at baseline and after 24 months. Longitudinal changes were assessed using Wilcoxon signed-rank tests and linear mixed-effects models. Results: Patients receiving tolvaptan were younger and had higher baseline TKV values than untreated patients. During follow-up, NLR, PLR, and SII decreased in the tolvaptan group, whereas these markers increased in untreated patients. eGFR declined in both groups but appeared less pronounced in patients receiving tolvaptan. TKV increased in both groups; however, the percentage increase in TKV was lower among patients receiving tolvaptan. Significant time × treatment interactions were observed for NLR, PLR, SII, and TKV. In the non-tolvaptan group, NLR at 24 months showed a significant positive association with TKV. Conclusions: Tolvaptan use was associated with differences in longitudinal changes in systemic inflammatory markers and kidney volume progression in ADPKD. Further prospective studies are needed to clarify the clinical relevance of these associations.